Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Docherty, Kieran F, Jhund, Pardeep S, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, DeMets, David L, Sabatine, Marc S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Desai, Akshay S, Diez, Mirta, Howlett, Jonathan G, Katova, Tzvetana, Ljungman, Charlotta E A, O’Meara, Eileen, Petrie, Mark C, Schou, Morten, Verma, Subodh, Vinh, Pham Nguyen, Solomon, Scott D, McMurray, John J V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327533/
https://www.ncbi.nlm.nih.gov/pubmed/32221582
http://dx.doi.org/10.1093/eurheartj/ehaa183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327533/
https://www.ncbi.nlm.nih.gov/pubmed/32221582
http://dx.doi.org/10.1093/eurheartj/ehaa183

Ejemplares similares